Literature DB >> 6683644

A phase II study of cisplatin in advanced gastric cancer.

M Beer, G Cocconi, G Ceci, M Varini, F Cavalli.   

Abstract

Twenty patients with recurrent or metastatic gastric adenocarcinoma and prior chemotherapy were treated with cisplatin, 60-120 mg/m2 as a 6-hr infusion repeated every 3 weeks. There were 4 partial responses in 18 evaluable patients. Seven patients had stable disease. Time to progression ranged from 6 to 28 weeks. Median WBC nadir was 3.2 X 10(3)/mm3 (range, 1.5-7.1) and platelet nadir 120 X 10(3)/mm3 (range, 13-220). A transient increase in serum creatinine was observed in 6 cases, and nausea and vomiting in all. We conclude that this drug is active in stomach cancer and that it warrants further trials in combination chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6683644     DOI: 10.1016/0277-5379(83)90003-2

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  13 in total

1.  Phase II trial of carboplatin and vinblastine in adenocarcinoma of the stomach.

Authors:  D Ginn; D Kelsen; M Eisenberger; R Heelan; G Magill
Journal:  Invest New Drugs       Date:  1990-08       Impact factor: 3.850

Review 2.  Cytotoxic drugs for gastric and colorectal cancer.

Authors:  D Cunningham
Journal:  BMJ       Date:  1989-12-16

3.  A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501).

Authors:  Norisuke Nakayama; Wasaburo Koizumi; Satoshi Tanabe; Tohru Sasaki; Katsunori Saigenji
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

4.  Phase II study of CHIP chemotherapy in advanced adenocarcinomas of the upper gastrointestinal tract.

Authors:  A S Goldenberg; D Kelsen; J Dougherty; G Magill
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

Review 5.  Update in cancer chemotherapy: gastrointestinal cancer, cancer of the stomach and carcinoid tumors.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1986-07       Impact factor: 1.798

6.  Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer.

Authors:  Shunichi Tsujitani; Kenji Fukuda; Nobuaki Kaibara
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

Review 7.  Cisplatin: a review of clinical applications and renal toxicity.

Authors:  D T Sleijfer; S Meijer; N H Mulder
Journal:  Pharm Weekbl Sci       Date:  1985-12-13

8.  Experimental and clinical studies on the intraperitoneal administration of cis-diamminedichloroplatinum (II) for peritoneal carcinomatosis caused by gastric cancers.

Authors:  T Furukawa; K Kumai; T Kubota; S Hirahata; H Shimizu; H Matsui; T Takahara; K Aizawa; S Shibata; A Shimada
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

Review 9.  Gastric cancer--the recognition of a chemosensitive tumour.

Authors:  D Cunningham
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640

10.  Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.

Authors:  J S Waters; A Norman; D Cunningham; J H Scarffe; A Webb; P Harper; J K Joffe; M Mackean; J Mansi; M Leahy; A Hill; J Oates; S Rao; M Nicolson; T Hickish
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.